2 results match your criteria: "Wuxi Hospital Affiliated of Nanjing University of Chinese Medicine[Affiliation]"
Prospects of anti-GD2 immunotherapy for retinoblastoma.
Front Immunol
December 2024
Affiliated Hospital of Shandong Second Medical University,School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Article Synopsis
- - Retinoblastoma is the most common eye tumor in young children, and existing treatments like chemotherapy and surgery can have serious side effects, including blindness and toxic reactions.
- - Immunotherapy, especially targeting the GD2 sphingolipid found on retinoblastoma cells, shows promise due to its lower toxicity and potential to improve patient quality of life.
- - Anti-GD2 therapies, such as the monoclonal antibody Dinutuximab, CAR-T therapy, GD2 vaccines, and nanoparticles are emerging as effective treatments, but there are still challenges to overcome in their application.
Identifying immune-related prognostic biomarkers in osteosarcoma: Development and validation of the tumor immune microenvironment risk model based on analysis of TCGA.
Environ Toxicol
March 2024
Department of Traumatology & Orthopedics, Wuxi Hospital Affiliated of Nanjing University of Chinese Medicine, Wuxi, China.
Article Synopsis
- The study focuses on osteosarcoma, a rare and aggressive cancer, aiming to identify immune-related prognostic biomarkers and create a model for predicting patient outcomes.
- Researchers analyzed data from 84 osteosarcoma samples, leading to the identification of a seven-gene TIMErisk model that correlates with patient survival, immune cell activity, and drug sensitivity.
- The findings emphasize the relevance of the tumor immune microenvironment in osteosarcoma and suggest that the TIMErisk model could assist in evaluating prognosis and immunotherapy responses.